CA2606258C - Neurotherapeutic azole compounds - Google Patents
Neurotherapeutic azole compounds Download PDFInfo
- Publication number
- CA2606258C CA2606258C CA2606258A CA2606258A CA2606258C CA 2606258 C CA2606258 C CA 2606258C CA 2606258 A CA2606258 A CA 2606258A CA 2606258 A CA2606258 A CA 2606258A CA 2606258 C CA2606258 C CA 2606258C
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- carbon atoms
- ethyl ester
- tetrazol
- carbamic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 | |
| US60/674,530 | 2005-04-22 | ||
| PCT/KR2006/001523 WO2006112685A1 (en) | 2005-04-22 | 2006-04-21 | Neurotherapeutic azole compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2606258A1 CA2606258A1 (en) | 2006-10-26 |
| CA2606258C true CA2606258C (en) | 2014-01-14 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2606258A Expired - Lifetime CA2606258C (en) | 2005-04-22 | 2006-04-21 | Neurotherapeutic azole compounds |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (2) |
| EP (1) | EP1879873B1 (2) |
| JP (1) | JP5035238B2 (2) |
| KR (1) | KR101286499B1 (2) |
| CN (1) | CN101228138B (2) |
| AR (1) | AR053065A1 (2) |
| AU (1) | AU2006237798B2 (2) |
| BE (1) | BE2021C524I2 (2) |
| BR (1) | BRPI0607529B8 (2) |
| CA (1) | CA2606258C (2) |
| DK (1) | DK1879873T3 (2) |
| ES (1) | ES2441765T3 (2) |
| FI (1) | FIC20210018I1 (2) |
| FR (1) | FR21C1027I2 (2) |
| MX (1) | MX2007013197A (2) |
| MY (1) | MY148589A (2) |
| NL (1) | NL301106I2 (2) |
| PL (1) | PL1879873T3 (2) |
| PT (1) | PT1879873E (2) |
| RU (1) | RU2418792C2 (2) |
| TW (1) | TWI398249B (2) |
| WO (1) | WO2006112685A1 (2) |
| ZA (1) | ZA200709994B (2) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| ES2379848T3 (es) * | 2007-05-14 | 2012-05-04 | Sk Biopharmaceuticals Co., Ltd. | Compuesto arilpiperazina arilalcanoil carbomoiloxi novedoso, composiciones farmacéuticas que comprenden el compuesto y método para tratar el dolor, ansiedad y depresión al administrar el compuesto |
| AU2008258599B2 (en) | 2007-06-05 | 2013-06-13 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| EP2285787B1 (en) * | 2008-06-05 | 2015-08-26 | SK Biopharmaceuticals Co., Ltd. | 3-substituted propanamine compounds |
| WO2010150946A1 (en) * | 2009-06-22 | 2010-12-29 | Sk Holdings Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| BR112012010670A2 (pt) | 2009-11-06 | 2016-04-12 | Sk Biopharmaceuticals Co Ltd | métodos para tratamento de distúrbio de défict de atenção/hiperatividade |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| AU2013202982C1 (en) * | 2012-01-06 | 2017-01-05 | Novartis Ag | Heterocyclic compounds and methods for their use |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI698415B (zh) * | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| EP3556365B1 (en) * | 2016-12-14 | 2025-07-02 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| US11033531B2 (en) * | 2016-12-14 | 2021-06-15 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome |
| KR102901908B1 (ko) * | 2016-12-14 | 2025-12-17 | 에스케이바이오팜 주식회사 | 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| MX2019006940A (es) * | 2016-12-14 | 2019-09-06 | Sk Biopharmaceuticals Co Ltd | Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. |
| ES2898457T3 (es) * | 2016-12-14 | 2022-03-07 | Sk Biopharmaceuticals Co Ltd | Comprimido de disgregación oral que comprende un compuesto de carbamato |
| CA3046458A1 (en) | 2016-12-14 | 2018-06-21 | Sk Biopharmaceuticals Co., Ltd. | Parenteral liquid preparation comprising carbamate compound |
| EP3556363B1 (en) * | 2016-12-14 | 2024-03-06 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation or treatment of pruritus |
| KR102900173B1 (ko) * | 2016-12-14 | 2025-12-12 | 에스케이바이오팜 주식회사 | 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도 |
| WO2019098633A1 (ko) * | 2017-11-14 | 2019-05-23 | 에스케이바이오팜 주식회사 | 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도 |
| MX2020004975A (es) * | 2017-11-14 | 2020-08-24 | Sk Biopharmaceuticals Co Ltd | Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia. |
| AU2018370164B2 (en) * | 2017-11-14 | 2024-08-15 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome |
| US11389429B2 (en) | 2017-11-14 | 2022-07-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating myotonia |
| PT3711758T (pt) * | 2017-11-14 | 2024-04-22 | Sk Biopharmaceuticals Co Ltd | Utilização de composto de carbamato para prevenir, aliviar ou tratar crise de ausência ou epilepsia que apresenta crise de ausência |
| EP3711760B1 (en) | 2017-11-14 | 2024-02-14 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| ES2978226T3 (es) * | 2018-09-21 | 2024-09-09 | Sk Biopharmaceuticals Co Ltd | Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático |
| EP3854392A4 (en) * | 2018-09-21 | 2022-08-17 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES |
| AU2019361856B2 (en) * | 2018-10-19 | 2024-11-07 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| BR112022009533A2 (pt) * | 2019-11-22 | 2022-08-02 | Sk Biopharmaceuticals Co Ltd | Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica |
| US20230338295A1 (en) * | 2020-08-06 | 2023-10-26 | Sk Biopharmaceuticals Co., Ltd. | Solid oral composition comprising carbamate compound, and preparation method therefor |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
| CN115716810B (zh) * | 2022-11-15 | 2026-02-13 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
| CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) * | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) * | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| AU657790B2 (en) * | 1991-08-22 | 1995-03-23 | Warner-Lambert Company | Amide tetrazole ACAT inhibitors |
| EP1406605B1 (en) * | 2001-06-25 | 2007-09-19 | SK Corporation | Carbamates of 2-heterocyclic-1,2-ethanediols |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 CA CA2606258A patent/CA2606258C/en not_active Expired - Lifetime
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh not_active Expired - Lifetime
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es not_active Expired - Lifetime
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en not_active Expired - Lifetime
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en not_active Expired
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko not_active Expired - Lifetime
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja not_active Expired - Lifetime
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en not_active Ceased
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
- 2021-06-28 BE BE2021C524C patent/BE2021C524I2/nl unknown
- 2021-07-06 FR FR21C1027C patent/FR21C1027I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2606258C (en) | Neurotherapeutic azole compounds | |
| US6037352A (en) | Muscarinic antagonists | |
| KR920005113B1 (ko) | 정신병치료제 1-플루오로페닐부틸-4-(2-피리미디닐)피페라진 유도체의 제조방법. | |
| US5602152A (en) | Benzoxepines | |
| CA2350722A1 (en) | 4-aroyl-piperidin-ccr-3 receptor antagonists iii | |
| WO2000042023A1 (en) | Substituted imidazoles, their preparation and use | |
| KR101890443B1 (ko) | Ｐ2ｘ4 수용체 길항제 | |
| CZ20031596A3 (cs) | Deriváty substituovaného 2-fenylaminoimidazolinfenylketonu jako IP antagonistická činidla | |
| JP3004727B2 (ja) | ドパミン作動性活性を有するベンゾイミダゾール誘導体 | |
| CA2146261A1 (en) | Sulfonamide derivatives of benzenefused, hydroxy substituted cycloalkyl and heterocyclic ring compounds | |
| EP2183227B1 (en) | 1,2,4-triazole derivatives as serotonergic modulators | |
| JPH08291112A (ja) | アリールアルキル−アミンおよびアミド | |
| JP5527668B2 (ja) | ３−置換プロパンアミン化合物 | |
| NO179513B (no) | 2-substituerte kinolylmetoksy-fenyleddiksyrederivater, legemidler inneholdende dem samt deres anvendelse for fremstilling av legemidler | |
| US5304563A (en) | 2-substituted quinolines, and their use in medicaments | |
| CA2002774A1 (en) | 1-aminoalkyl-3-oxysubstituted-4-aryl-1,3,4,5-tetrahydro-2h- 1,3-benzodiazepine-2-ones, a process for their preparation and their use as medicaments | |
| CA2728949C (en) | Thiophene containing analogues of fluconazole as antifungal agents and process thereof | |
| WO2015041620A1 (en) | Antifungal compounds of (arylalkyl) azole derivatives in the structure of oxime ester | |
| MXPA01005034A (en) | Pyrrolidine derivatives-ccr-3 receptor antagonists | |
| HU185790B (en) | Process for the preparation of new triazole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD Year of fee payment: 19 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 |